Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why

09.12.24 18:45 Uhr

Werte in diesem Artikel

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.Our proprietary system currently recommends Exelixis (EXEL) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.Here are three of the most important factors that make the stock of this drug developer a great growth pick right now.Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.While the historical EPS growth rate for Exelixis is 6.5%, investors should actually focus on the projected growth. The company's EPS is expected to grow 114.3% this year, crushing the industry average, which calls for EPS growth of 23.1%.Impressive Asset Utilization RatioAsset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric exhibits how efficiently a firm is utilizing its assets to generate sales.Right now, Exelixis has an S/TA ratio of 0.73, which means that the company gets $0.73 in sales for each dollar in assets. Comparing this to the industry average of 0.23, it can be said that the company is more efficient.While the level of efficiency in generating sales matters a lot, so does the sales growth of a company. And Exelixis looks attractive from a sales growth perspective as well. The company's sales are expected to grow 17.3% this year versus the industry average of 0%.Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.There have been upward revisions in current-year earnings estimates for Exelixis. The Zacks Consensus Estimate for the current year has surged 0.9% over the past month.Bottom LineExelixis has not only earned a Growth Score of A based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.This combination positions Exelixis well for outperformance, so growth investors may want to bet on it.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Exelixis

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Exelixis

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Exelixis Inc.

Analysen zu Exelixis Inc.

DatumRatingAnalyst
22.02.2019Exelixis Market PerformBMO Capital Markets
11.05.2018Exelixis BuyNeedham & Company, LLC
17.10.2017Exelixis BuyNeedham & Company, LLC
17.10.2017Exelixis OutperformRBC Capital Markets
15.09.2017Exelixis OutperformRBC Capital Markets
DatumRatingAnalyst
22.02.2019Exelixis Market PerformBMO Capital Markets
11.05.2018Exelixis BuyNeedham & Company, LLC
17.10.2017Exelixis BuyNeedham & Company, LLC
17.10.2017Exelixis OutperformRBC Capital Markets
15.09.2017Exelixis OutperformRBC Capital Markets
DatumRatingAnalyst
17.08.2011Exelixis holdStifel, Nicolaus & Co., Inc.
18.11.2009Exelixis neutralMerriman Curhan Ford & Co
14.08.2008Exelixis ErsteinschätzungBanc of America Securities LLC
04.09.2007Exelixis DowngradeWachovia Sec
10.05.2005Update Exelixis Inc.: Market PerformJMP Securities
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Exelixis Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"